BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 29943218)

  • 1. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
    García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO
    World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
    Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
    Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy.
    Mazzone E; Nazzani S; Knipper S; Tian Z; Preisser F; Gallina A; Soulières D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Wisnivesky J; Karakiewicz PI
    Eur J Surg Oncol; 2019 Jul; 45(7):1253-1259. PubMed ID: 30755341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical radiotherapy in older patients with muscle invasive bladder cancer.
    Wujanto C; Tey J; Chia D; Ho F; Ooi KH; Wong AS; Soon YY; Lim K
    J Geriatr Oncol; 2019 Mar; 10(2):292-297. PubMed ID: 30630748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
    J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer.
    D'Andrea D; Soria F; Zehetmayer S; Stangl-Kremser J; Grubmüller B; Abufaraj M; Gust K; Kimura S; Babjuk M; Goldner GM; Shariat SF
    Scand J Urol; 2020 Feb; 54(1):52-57. PubMed ID: 31975654
    [No Abstract]   [Full Text] [Related]  

  • 11. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
    Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
    JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
    Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
    Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy.
    Zapatero A; Martin De Vidales C; Arellano R; Ibañez Y; Bocardo G; Perez M; Rabadan M; García Vicente F; Cruz Conde JA; Olivier C
    Urology; 2012 Nov; 80(5):1056-62. PubMed ID: 22999456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Uhlig A; Strauss A; Seif Amir Hosseini A; Lotz J; Trojan L; Schmid M; Uhlig J
    Eur Urol Focus; 2018 Dec; 4(6):924-936. PubMed ID: 28888813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
    Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
    Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival.
    Russell B; Sherif A; Häggström C; Josephs D; Kumar P; Malmström PU; Van Hemelrijck M
    Scand J Urol; 2019 Aug; 53(4):206-212. PubMed ID: 31174452
    [No Abstract]   [Full Text] [Related]  

  • 20. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.
    Hermans TJ; Fransen van de Putte EE; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; de Wit R; Beerepoot LV; Verhoeven RH; van Rhijn BW
    Eur J Cancer; 2016 Dec; 69():1-8. PubMed ID: 27814469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.